In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dexela Ltd.

Division of PerkinElmer Inc.
www.dexelaimaging.com

Latest From Dexela Ltd.

Real Time Tomography LLC

Real Time Tomography has developed image processing and reconstruction software for use with next-generation digital 2D and 3D breast imaging systems that allows for real-time interaction with complex data in three dimensions, and provides higher image quality and reduced data storage.

Medical Device

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2011

Medical device companies raised a total of $906 million in Q3, while in vitro diagnostic/research developers took in $72 million. The top M&As in each segment were private buyouts of public companies: Kinetic Concepts for $6.3 billion and Immucor for $1.9 billion.

Medical Device Deals

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2008

Highlights from the Q3 2008 review of device and diagnostics dealmaking: Led by late-stage rounds, financing for medical device firms--at just over $1bn--showed a slight improvement over the last quarter. IPOs and follow-ons were noticeably absent in Q3, reminiscent of a time in 2003 when the IPO window closed. Not even one of the 13 device M&A transactions reached the billion-dollar mark, but the largest deal, GE Healthcare's buy of Vital Signs for $990mm, came close. In vitro diagnostics/research financings doubled to $643mm led by Illumina's $343mm FOPO. M&A activity in this industry was scant with a mere three transactions. However, Nanogen's reverse merger with Elitech Group--worth $99mm-beat the median M&A deal price ($60mm) over the past five years. Interestingly many in vitro diagnostics players turned to alliances with tech transfer entities in hopes of filling their pipelines.
BioPharmaceutical Medical Device

Breast Cancer: Improving the Odds

Breast cancer is the most common type of female cancer and the number two cancer killer in US women. Treatment options continue to expand and researchers are making steady advancements in cancer detection that they hope will one day enable most breast cancer cases to be diagnosed an an early, very curable stage.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • X-ray
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • PerkinElmer Inc.
  • Senior Management
  • Ed Bullard, CEO
    John Kerr, Dir., Finance
    Roman Janer, SVP, Prod. Dev.
    Jamshid Dehmeski, CSO
  • Contact Info
  • Dexela Ltd.
    Phone: (44) 845 229 7750
    1 Water Ln.
    Camden Town
    London, NW1 8NZ
    UK
UsernamePublicRestriction

Register